SCHEMBL5149503

SCHEMBL5149503

CCC(c1ccc(Nc2nccc3cnccc23)cc1)[C@H](N)C(=O)O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.37
RAB9A P51151 5/20 0.36
NPC1 O15118 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
ALDH1A1 P00352 2/20 0.36
TP53 P04637 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDR P35968 2/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
ROCK2 O75116 5/20 0.36
ROCK1 Q13464 2/20 0.36
CSNK2A1 P68400 3/20 0.35
CSNK2A2 P19784 2/20 0.35
CSNK2B P67870 2/20 0.35
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264737 1.00 TRPV1 (0.37) TRPV1RAB9ANPC1SMN1; SMN2ALDH1A1
SCHEMBL5147750 0.93 RAB9A (0.37) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL3835600 0.82 CSNK2A1 (0.38) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL2980728 0.82 CSNK2A1 (0.38) RAB9ANPC1SMN1; SMN2ALDH1A1TP53
SCHEMBL7168182 0.81 ROCK2 (0.38) RAB9ANPC1SMN1; SMN2KDRKMT2A
SCHEMBL7168174 0.81 ROCK2 (0.38) RAB9ANPC1SMN1; SMN2KDRKMT2A
SCHEMBL5147804 0.80 EGFR (0.38) TRPV1KDRCSNK2A1CSNK2A2CSNK2B
SCHEMBL5149368 0.79 ITGB1 (0.34) TRPV1RAB9ANPC1SMN1; SMN2KDR
SCHEMBL2986240 0.78 SLC7A5 (0.42) TRPV1ROCK2ROCK1HDAC3HDAC1
SCHEMBL7105541 0.78 SLC7A5 (0.42) TRPV1ROCK2ROCK1HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 TRPV1 2450/4885RAB9A 2226/4885NPC1 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.